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INTRODUCTION
The imidazopyridine zolpidem, introduced to the market in 1988, is a non-benzodiazepine hypnotic acting as an agonist on the central GABA-A benzodiazepine receptor complex 1 . Zolpidem is considered to have a lower abuse and dependence-potential than benzodiazepines, and is therefore a widely used medication in the short-term treatment of insomnia. Zolpidem binds allosterically to the alpha-1 receptor subtype of the receptor complex and activates chloride channels thus potentiating GABA, the main inhibitory neurotransmitter in the central nervous system. The recommended therapeutic dose is 10 mg in the general population and 5mg in people older than 65 years of age. At these doses, zolpidem decreases sleep latency without the anxiolytic, muscle relaxant or anticonvulsant effects associated with benzodiazepines. As with benzodiazepines, zolpidem's central nervous system depressant effects can be antagonized by flumazenil 1 . Zolpidem is metabolized by the CYP3A and CYP1A2 isoenzymes. Bioavailability after oral administration is 70%, and maximum concentration appears around 30 minutes after administration. Excretion occurs mainly as inactive metabolite in urine (56%) and feces (37%), with an elimination half-life of 2.4 hours 1 . Zolpidem is commonly used recreationally, often in combination with alcohol causing a euphoric feeling, visual distortions, hallucinations and decreased anxiety in people taking high doses. However, cases of complex behavior, sleep related amnestic activities and psychotic symptoms have also been reported and described in patients taking therapeutic doses. Patients have been known to eat vast amounts of food during sleep [2] [3] [4] [5] [6] [7] [8] [9] , make phone calls 2 , wax their legs 2 , drive their cars 3, 8 and experience visual hallucinations [10] [11] [12] [13] [14] [15] [16] after 10 mg of zolpidem. These behaviors are usually amnestic or partially-amnestic, and in many cases they decrease the patients quality of life due to injuries sustained during sleepwalking and unexplainable weight gain due to amnestic nocturnal eating.
The aim of this work is to re-evaluate cases of such behavior described in the literature, with emphasis on common traits, patterns and predisposing factors in patients experiencing such behaviors.
METHODS
A systematic review based on a Medline literature search was conducted including the years 1966-2012 to assemble all available clinical case reports that were then analyzed for typical features of abuse and dependence according to prespecified criteria. Only case reports were of interest, and clinical studies were excluded. Computerized databases i.e. Pubmed, PsychInfo, the Cochrane Library and SciELO were searched using the following terms: "zolpidem" cross-referenced with "psychosis", "adverse drug reaction", "complex amnestic behavior", "sleep".
RESULTS
The data presented in the Table 1 show a clear trend in patients affected by sleep related amnestic behavior after zolpidem intake in therapeutic doses. Out of 47 cases reported, 27 were women.
Out of those, 13 were reported to be suffering from depression, whilst information on any psychiatric diagnosis was missing in several of the remaining female reports. Use of alcohol, drugs or cigarettes was seen in 6 cases all together. However, in women with mood disorders receiving antidepressants no substance use was reported. It seems from the data that women affected with mood disorders are more prone to sleep related amnestic behavior as a side effect of therapeutic doses of zolpidem. However, a substantial number of cases was accompanied by psychotropic concomitant medication with a predominance of monoaminergic drugs.
DISCUSSION
From the material studied, it seems females treated with zolpidem for insomnia are more likely to develop sleep related amnestic behaviors such as sleep eating and visual hallucinations than are males. In 9 out of 27 females, there was a somatic c o m o r b i d i t y r e p o r t e d , m a k i n g s o m a t i c comorbidities a significant factor contributing to the onset of sleep related amnestic behaviors related to zolpidem.
In the material covered, women were reported as having more complex behavioral side effects than men, especially those related to sleep eating and visual hallucinations as the only male patient in the cases studied who displayed visual hallucinations had recently discontinued a long drug abuse 10 . Women were also overrepresented amongst the patients, who reported nocturnal eating. The increased susceptibility of women to zolpidem behavioral side effects has been reported before in the literature, although in supra-therapeutic doses. Here we find that even in low therapeutic doses (as low as 5 mg) behavioral side effects have been reported 15 .
The interruption of treatment with zolpidem led to regression of the behaviors in all reported patients and some began displaying the behavior again when recommencing the treatment. The sleep related amnestic behavior usually started about 30 minutes after zolpidem ingestion. Only three cases were associated with ingestion of alcohol 7, 8, 17 and none of the patients reported intake of any drugs on the day of the incident described. Only one patient reported previous alcohol abuse 18 . The effects of zolpidem on NREM sleep have been described before 2 , however an in depth exploration of the factors predisposing to such behaviors related to zolpidem seems to be missing. The majority of females were taking therapeutic doses of no more than 10 mg before bedtime and One female did not report any visual hallucinations until her fluvoxamine dose was increased from 50 mg to 150 mg 13 which seemed to be associated with the pharmacokinetic interaction. None of the females, who presented with visual hallucinations, was reported to have any prior ophthalmic disease. Some females experiencing visual hallucinations when re-challenged with a subtherapeutic dose of zolpidem, experienced similar symptoms although, of lower magnitude 14 . Sleep related amnestic behavior in subjects taking therapeutic doses of zolpidem is clearly more closely associated with females with mood disorders. We hypothesize that this phenomenon could be due to the gender-dependent pharmacokinetics of z o l p i d e m . C u b a ł a e t a l . 19 s u g g e s t t h e pharmacokinetics of zolpidem seems to be related to endocrine factors associated with CYP3A4 activity. CYP3A, being the major enzymes involved in metabolism of xenobiotic substances in the human body, is also responsible for the biotransformation of zolpidem. The low levels of testosterone in women compared to men may contribute to lower CYP3A activity, and thus lower biotransformation of zolpidem, and would thereby explain why women achieve a 50% higher plasma concentration of zolpidem than men, thus rendering them more vulnerable to side effects. The fact that many of the women reported onset of amnestic behavior to be around 30 minutes after intake of zolpidem seems to be directly related to plasma concentration and half-life. Moreover, it may also be associated with the fact that insomnia and depression are more prevalent in women and women's compliance is substantially higher. Thus, the corresponding prescription rates for psychotropic agents in women along with the sex associated drug exposure are higher in that group and contribute to the observed sex related adverse drug reactions 1, 19 . From the pharmacodynamic point of view it could have been expected that reported cases would show a great correlation between drug and alcohol abuse and zolpidem's amnestic side effects. However, none of the women reported any form of abuse and it would seem any adverse reactions are more related to individual characteristics.
The monoaminergic hypothesis of depression remains the dominant one. Deficiency in serotonin and norepinephrine in the brain is the proposed causative factor in development of depression and to date is the major mechanism suggested in the mode of action of antidepressants 20 . Monoamine reuptake inhibitors attenuate GABA-ergic transmission facilitating neuronal activation and the release of dopamine 21 . This effect could contribute to behavioral and psychotic disturbances in the course of treatment with antidepressants as well as in individuals predisposed to decreased monoaminergic neurotransmission levels. From the cases studied, out of the 17 women who presented with side effects of zolpidem, 10 reported concomitant depression and a significant proportion of the patients reviewed were under concomitant treatment with antidepressant medication. This suggests that low monoaminergic levels might predispose patients (especially females) with concomitant depression to adverse reactions to zolpidem even at therapeutic doses.
Complex parasomnia-like behaviors have also been reported, such as driving, talking, eating, and engaging in sex. Post marketing studies of zolpidem have found the incidence of sleep related amnestic behaviors to be low, occurring in less than one percent of cases, although a recent case series found it to be higher, at five percent. The incidence of hallucinations with zolpidem is reported to occur in less than one percent of patients. Because these behaviors are accompanied by amnesia, it is likely that they are underreported 15 . Zolpidem may induce or aggravate parasomnias, such as sleepwalking, a distinct phenomenon wherein sleep related amnestic behaviors take place during electroencephalographically verifiable slowwave sleep (non-REM Stages 3-4). These behaviors appear purposeless to outside observers. Speech is typically incoherent. FDA data indicate that zolpidem does not significantly change sleep architecture, but it has been reported that it decreases REM sleep with a corresponding increase in non-REM sleep time. This increase in total non-REM sleep time may increase the risk of somnambulistic behaviors. In a recent study of outpatients with sleep disorders, use of zolpidem was positively correlated with sleepwalking and sleep-related eating 15, 22 . Zolpidem-associated amnestic behaviors are observed both during the daytime and at sleeping times. The classification of the behavior as parasomnia depends on the time of ingestion, the incidence of sleep prior to the behavior, and on patient characteristics. Thus, the observed activity may fall into the category of parasomia or automatism. Pressman 23 proposed a hypothetical mechanism of zolipdem-associated amnestic behaviors where the onset of the event could be parasomnia, but in the course of the event the sleeprelated elements disappear followed by a complex automatic state leaving the patient intoxicated. That concept emphasizes the sequence of events after the moment of zolpidem ingestion with few definable motifs for the complex behaviors observed.
Finally, there is generally something unique about zolpidem's neurochemistry, which results in relatively more side effects along with abuse and dependence. Zolpidem is listed as psychotropic substance under international control in Schedule IV of the International Narcotics Control Board while other Z-drugs are not listed for prevention of non-licensed use. Little is known about differences between zolpidem and other Z-drugs in scope of the abuse and dependence potential. However, naturalistic studies indicate the drug is misused for its paradoxical effect as it produces stimulation and anxiolysis 24 .
CONCLUSION
Sleep-related amnestic behaviors associated with zolpidem need to be taken into consideration as an adverse drug reaction before drug prescription, and an evaluation of patient potential risk factors should be undertaken. The risk for the complex behaviors associated with zolpidem seems to be higher in women and in cases of concomitant medication with monoaminergic drugs. Physicians should be attentive to the incidence of the unusual complex adverse effects of zolpidem.
